{
  "docId": "019dd923-5ca1-7489-b638-42055a53b541",
  "docSlug": "1774c324fda45105",
  "documentTitle": "Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report",
  "authorId": "LEK",
  "authorName": "L.E.K.",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 11,
  "pageCount": 58,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "pain_points",
  "function": "diagnose",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": [
    "headline_text",
    "icon_grid"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5ca1-7489-b638-42055a53b541/11",
  "deckHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541",
  "deckJsonHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json",
  "deckAnchorHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.14,
        "w": 0.925,
        "x": 0.037,
        "y": 0.27
      },
      "kind": "list",
      "text": "COVID-19 uncertainties: Difficulties in patient recruitment; Potential trial progress delay due to regional lockdowns",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "49c932ed-4b62-453a-8fa2-b60bf7d344d4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.14,
        "w": 0.925,
        "x": 0.037,
        "y": 0.63
      },
      "kind": "list",
      "text": "Homogeneous competition: Homogeneous competition of Chinese pharmaceutical companies, especially around popular targets such as PD-1/L1",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6e5b3d91-203f-4226-8e57-3b8434dfc198",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.14,
        "w": 0.925,
        "x": 0.037,
        "y": 0.81
      },
      "kind": "list",
      "text": "Regulatory pressure: Stringent R&D requirements such as potential head-to-head trial for oncology drug; Price and profit cutdown brought by VBP and NRDL negotiation",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "707a3b6c-c8ee-4555-bc15-8b307f90df39",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.14,
        "w": 0.925,
        "x": 0.037,
        "y": 0.45
      },
      "kind": "list",
      "text": "Funding challenges: Hard to obtain funding as financial investors become more cautious due to economy slowdown and price pressure in Chinese stock markets",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "883c3bd7-b473-4260-b5fa-2ddd3eef01fb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.25,
        "x": 0.037,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Source: DXY, Trialtrove, L.E.K. interviews and analysis",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0972b177-01ea-4429-bf65-b9d91a23de25",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.925,
        "x": 0.037,
        "y": 0.06
      },
      "kind": "title",
      "text": "Meanwhile, headwinds facing China clinical development are also significant: COVID-19 uncertainties, funding challenges, homogeneous competition and regulatory pressure",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "927ddb73-64da-4570-b588-ce342597de2b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.037,
        "y": 0.21
      },
      "kind": "title",
      "text": "Challenges of China pharmaceutical R&D",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f3c5fc58-87f7-45a9-8feb-70315f234f6d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "436dd1af-d7d9-47b6-a8dd-021cc1911876",
      "evidence": "list/bullet: Regulatory pressure: Stringent R&D requirements such as potential head-to-head trial for oncology drug; Price and profit cutdown brought by VBP and NRDL negotiation",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 11,
      "from": 6,
      "beatId": "2e308d53-f564-4d1b-a207-755a279e3246",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Problem & Complication",
      "beatSlug": "consultants-gambit-problem-complication",
      "evidence": "The report discusses the challenges facing China's clinical development, including COVID-19 uncertainties and funding challenges.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 11,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "90bfd894-313f-433e-b1a3-d0f790c2452f",
      "evidence": "The report highlights the challenges facing China's clinical development, including homogeneous competition and a need for more innovative and differentiated therapies.",
      "position": 0,
      "objective": "What are the consequences of not pivoting to high-quality growth in China's clinical trials?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}